Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

179 trials with published results (33%)

Research Maturity

398 completed trials (74% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

2.2%

12 terminated out of 535 trials

Success Rate

97.1%

+10.5% vs benchmark

Late-Stage Pipeline

37%

196 trials in Phase 3/4

Results Transparency

45%

179 of 398 completed with results

Key Signals

179 with results97% success12 terminated

Data Visualizations

Phase Distribution

487Total
Not Applicable (109)
Early P 1 (12)
P 1 (84)
P 2 (86)
P 3 (103)
P 4 (93)

Trial Status

Completed398
Unknown61
Not Yet Recruiting21
Withdrawn17
Recruiting17
Terminated12

Trial Success Rate

97.1%

Benchmark: 86.6%

Based on 398 completed trials

Clinical Trials (536)

Showing 20 of 20 trials
NCT07753811Not ApplicableCompleted

Effect of Oral Isotretinoin on Ocular Surface and Meibomian Glands

NCT07752368Not ApplicableCompleted

A Clinical Trial Examining the Efficacy of a Novel Acne Treatment Serum

NCT07224633Not ApplicableCompletedPrimary

A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin

NCT07524946Phase 4RecruitingPrimary

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT05080764Phase 2CompletedPrimary

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT07673094Early Phase 1Not Yet RecruitingPrimary

Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris

NCT07652112Not ApplicableCompletedPrimary

AI-Generated Acne Vulgaris Learning Material Study

NCT06415279Phase 4CompletedPrimary

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

NCT07639073Phase 4Not Yet RecruitingPrimary

Low-Dose Versus Conventional-Dose Oral Isotretinoin for Acne Vulgaris

NCT04466527Not ApplicableTerminatedPrimary

Laser Treatment of Moderate to Severe Acne Vulgaris

NCT07244887Phase 4CompletedPrimary

Randomized, Triple-Blind, Vehicle-Controlled Trial of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris

NCT06447480Phase 3RecruitingPrimary

Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients

NCT06141330Not ApplicableCompletedPrimary

Vitamin D Supplementation in Acne

NCT06225570Early Phase 1RecruitingPrimary

Weekly Isotretinoin vs Tetracycline for Moderate Acne

NCT05891795Phase 1Active Not RecruitingPrimary

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

NCT07544251Phase 4RecruitingPrimary

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

NCT07539129Not ApplicableNot Yet RecruitingPrimary

Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation

NCT07474883Early Phase 1Recruiting

Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris

NCT07205107Active Not RecruitingPrimary

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

NCT07504822Phase 1Not Yet RecruitingPrimary

Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris

Scroll to load more

Research Network

Activity Timeline